Kanada - enska - Health Canada

pro doc limitee - clomipramine hydrochloride - tablet - 10mg - clomipramine hydrochloride 10mg - tricyclics and other norepinephrine-reuptake inhibitors

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - clomipramine hydrochloride 10mg;   - capsule - 10 mg - active: clomipramine hydrochloride 10mg   excipient: gelatin capsule ink lactose monohydrate magnesium stearate maize starch povidone sodium laurilsulfate sodium starch glycolate - the treatment of depressive states (in adults only) including endogenous, reactive, neurotic, organic, masked and involutional forms of depression, depression associated with schizophrenia and personality disorders, depressive syndromes due to presenility or senility, chronic painful conditions, and chronic somatic diseases, and depressive mood disorders of a reactive, neurotic or psychopathic nature. chronic painful conditions

Ástralía - enska - APVMA (Australian Pesticides and Veterinary Medicines Authority)

mavlab pty. ltd. - clomipramine hydrochloride - unknown - clomipramine hydrochloride azepine active 0.0 - active constituent

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - clomipramine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; hypromellose; macrogol 3350; titanium dioxide; iron oxide yellow; carnauba wax - major depression. obsessive-compulsive disorders and phobias in adults. cataplexy associated with narcolepsy.

Bandaríkin - enska - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - clomipramine hydrochloride capsules are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (ocd). the obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the dsm-iii-r (circa 1989) diagnosis of ocd. obsessions are recurrent, persistent ideas, thoughts, images, or impulses that are ego-dystonic. compulsions are repetitive, purposeful, and intentional behaviors performed in response to an obsession or in a stereotyped fashion, and are recognized by the person as excessive or unreasonable. the effectiveness of clomipramine hydrochloride capsules for the treatment of ocd was demonstrated in multicenter, placebo-controlled, parallel-group studies, including two 10-week studies in adults and one 8-week study in children and adolescents 10 to 17 years of age. patients in all studies had moderate-to-severe ocd (dsm-iii), with mean baseline ratings on the yale-brown obsessive compulsive scale (ybocs) ranging from 26 to 28 and a mean baseline rating of 10 on the nimh clinical global obsessive compulsive scale (nimh-oc). patients taking cmi experienced a mean reduction of approximately 10 on the ybocs, representing an average improvement on this scale of 35% to 42% among adults and 37% among children and adolescents. cmi-treated patients experienced a 3.5 unit decrement on the nimh-oc. patients on placebo showed no important clinical response on either scale. the maximum dose was 250 mg/day for most adults and 3 mg/kg/day (up to 200 mg) for all children and adolescents. the effectiveness of clomipramine hydrochloride capsules for long-term use (i.e. for more than 10 weeks) has not been systematically evaluated in placebo-controlled trials. the physician who elects to use clomipramine hydrochloride capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see dosage and administration ). clomipramine hydrochloride capsules are contraindicated in patients with a history of hypersensitivity to clomipramine hydrochloride or other tricyclic antidepressants. monoamine oxidase inhibitors (maois) the use of maois intended to treat psychiatric disorders with clomipramine hydrochloride or within 14 days of stopping treatment with clomipramine hydrochloride is contraindicated because of an increased risk of serotonin syndrome. the use of clomipramine hydrochloride within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated (see  warnings and dosage and administration ). starting clomipramine hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see  warnings and dosage and administration ). myocardial infarction clomipramine hydrochloride is contraindicated during the acute recovery period after a myocardial infarction. clomipramine hydrochloride has not been systematically studied in animals or humans for its potential for abuse, tolerance, or physical dependence. while a variety of withdrawal symptoms have been described in association with clomipramine hydrochloride discontinuation (see precautions, withdrawal symptoms ), there is no evidence for drug-seeking behavior, except for a single report of potential clomipramine hydrochloride abuse by a patient with a history of dependence on codeine, benzodiazepines, and multiple psychoactive drugs. the patient received clomipramine hydrochloride for depression and panic attacks and appeared to become dependent after hospital discharge. despite the lack of evidence suggesting an abuse liability for clomipramine hydrochloride in foreign marketing, it is not possible to predict the extent to which clomipramine hydrochloride might be misused or abused once marketed in the u.s. consequently, physicians should carefully evaluate patients for a history of drug abuse and follow such patients closely.

Írland - enska - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - clomipramine hydrochloride - capsule - 10 milligram(s) - non-selective monoamine reuptake inhibitors; clomipramine

Malta - enska - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - clomipramine hydrochloride - hard capsule - clomipramine hydrochloride 10 mg - psychoanaleptics

Malta - enska - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - clomipramine hydrochloride - hard capsule - clomipramine hydrochloride 10 mg - psychoanaleptics

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - clomipramine hydrochloride 10mg;   - film coated tablet - 10 mg - active: clomipramine hydrochloride 10mg   excipient: colloidal silicon dioxide dispersed yellow 15093 anstead copovidone hypromellose   lactose monohydrate macrogol 8000 magnesium stearate maize starch microcrystalline cellulose povidone purified talc   sucrose titanium dioxide

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

viatris limited - clomipramine hydrochloride 10mg - film coated tablet - 10 mg - active: clomipramine hydrochloride 10mg excipient: lactose monohydrate magnesium stearate